Search Results - "Xiong, Henry"

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma by RATAIN, Mark J, EISEN, Tim, ROWINSKY, Eric, ABBRUZZESE, James L, CHENGHUA XIA, SIMANTOV, Ronit, SCHWARTZ, Brian, O'DWYER, Peter J, STADLER, Walter M, FLAHERTY, Keith T, KAYE, Stan B, ROSNER, Gary L, GORE, Martin, DESAI, Apurva A, PATNAIK, Amita, XIONG, Henry Q

“…This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and…”
Get full text

Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases by VAUTHEY, Jean-Nicolas, PAWLIK, Timothy M, RISIO, Mauro, MURATORE, Andrea, CAPUSSOTTI, Lorenzo, CURLEY, Steven A, ABDALLA, Eddie K, RIBERO, Dario, WU, Tsung-Teh, ZORZI, Daria, HOFF, Paulo M, XIONG, Henry Q, ENG, Cathy, LAUWERS, Gregory Y, MINO-KENUDSON, Mari

“…Chemotherapy before resection of hepatic colorectal metastases (CRM) may cause hepatic injury and affect postoperative outcome. Four hundred six patients…”
Get full text

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy by Varadhachary, Gauri R, Tamm, Eric P, Abbruzzese, James L, Xiong, Henry Q, Crane, Christopher H, Wang, Huamin, Lee, Jeffrey E, Pisters, Peter W T, Evans, Douglas B, Wolff, Robert A

“…With recent advances in pancreatic imaging and surgical techniques, a distinct subset of pancreatic tumors is emerging that blurs the distinction between…”
Get full text

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies by Javle, Milind M, Shroff, Rachna T, Xiong, Henry, Varadhachary, Gauri A, Fogelman, David, Reddy, Shrikanth A, Davis, Darren, Zhang, Yujian, Wolff, Robert A, Abbruzzese, James L

“…The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an…”
Get full text

Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial by XIONG, Henry Q, ROSENBERG, Arthur, LOBUGLIO, Albert, SCHMIDT, William, WOLFF, Robert A, DEUTSCH, John, NEEDLE, Michael, ABBRUZZESE, James L

“…To determine the response rate, time to disease progression, survival duration and rate, and toxicity with the combination of cetuximab and gemcitabine in…”
Get full text

Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head by VARADHACHARY, Gauri R, WOLFF, Robert A, LEE, Jeffrey H, ROSS, William A, TAMM, Eric P, BHOSALE, Priya R, KRISHNAN, Sunil, DAS, Prajnan, HO, Linus, XIONG, Henry, ABBRUZZESE, James L, EVANS, Douglas B, CRANE, Christopher H, SUN, Charlotte C, LEE, Jeffrey E, PISTERS, Peter W. T, VAUTHEY, Jean-Nicolas, ABDALLA, Eddie, HUAMIN WANG, STAERKEL, Gregg A

“…We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy…”
Get full text

A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial by Ko, Andrew H., Murphy, Patrick B., Peyton, James D., Shipley, Dianna L., Al‐Hazzouri, Ahmed, Rodriguez, Francisco A., Womack, Mark S., Xiong, Henry Q., Waterhouse, David M., Tempero, Margaret A., Guo, Shuangli, Lane, Cassie M., Earwood, Chris, DeBusk, Laura M., Bendell, Johanna C.

“…Lessons Learned The addition of the heat shock protein 27 (Hsp27)‐targeting antisense oligonucleotide, apatorsen, to a standard first‐line chemotherapy regimen…”
Get full text

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer by Xiong, Henry Q., Varadhachary, Gauri R., Blais, Joan C., Hess, Kenneth R., Abbruzzese, James L., Wolff, Robert A.

“…BACKGROUND. To the authors' knowledge, there is no established second‐line chemotherapy for patients with pancreatic cancer who have received gemcitabine‐based…”
Get full text

Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity by Wei, Daoyan, Wang, Liwei, He, Yanjuan, Xiong, Henry Q, Abbruzzese, James L, Xie, Keping

“…The aggressive biology of human pancreatic adenocarcinoma has been linked with overexpression of vascular endothelial growth factor (VEGF). Constitutive…”
Get full text

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis by DAOYAN WEI, XIANGDONG LE, KEPING XIE, LEIZHEN ZHENG, LIWEI WANG, FREY, Jennifer A, GAO, Allen C, ZHIHAI PENG, SUYUN HUANG, XIONG, Henry Q, ABBRUZZESE, James L

“…Expression of vascular endothelial growth factor (VEGF), a key angiogenic protein, has been linked with pancreatic cancer progression. However, the molecular…”
Get full text

Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer by CRANE, Christopher H, ELLIS, Lee M, CHARNSANGAVEJ, Chusilp, DELCLOS, Marc E, O'REILLY, Michael, LEE, Jeffrey E, WOLFF, Robert A, ABBRUZZESE, James L, AMOS, Christina, XIONG, Henry Q, HO, Linus, EVANS, Douglas B, TAMM, Eric P, NG, Chaan, PISTERS, Peter W. T

“…To study the safety of bevacizumab with capecitabine-based chemoradiotherapy. Patients with inoperable pancreatic adenocarcinoma received bevacizumab 2 weeks…”
Get full text

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer by Mehrvarz Sarshekeh, Amir, Xiong, Henry Q., Iizuka, Kenzo, Hochster, Howard S., Kopetz, Scott

“…Summary Background DFP-10917 is a cytotoxic deoxycytidine analogue that causes DNA fragmentation, G 2 /M–phase arrest, and apoptosis. This agent has been shown…”
Get full text

Aggresome disruption : A novel strategy to enhance bortezomib- induced apoptosis in pancreatic cancer cells by NAWROCKI, Steffan T, CAREW, Jennifer S, XIONG, Henry, ABBRUZZESE, James L, MCCONKEY, David J, PINO, Maria S, HIGHSHAW, Ralph A, ANDTBACKA, Robert H. I, DUNNER, Kenneth, PAL, Ashutosh, BORNMANN, William G, CHIAO, Paul J, PENG HUANG

“…The proteasome inhibitor bortezomib (formerly known as PS-341) recently received Food and Drug Administration approval for the treatment of multiple myeloma,…”
Get full text

Epidermal growth factor receptor-targeted therapy for pancreatic cancer by Xiong, Henry Q., Abbruzzese, James L.

“…Epidermal growth factor receptor (EGFR) plays an important role in tumor development and maintenance. It is a cell surface molecule that mediates signal…”
Get full text

Molecular targeting therapy for pancreatic cancer by XIONG, Henry Q

“…Pancreatic carcinogenesis is driven by multiple genetic and epigenetic changes. The epidermal growth factor receptor (EGFR) and its downstream signaling…”
Get full text

Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results by Murthy, Ravi, Xiong, Henry, Nunez, Rodolfo, Cohen, Alan C, Barron, Bruce, Szklaruk, Janio, Madoff, David C, Gupta, Sanjay, Wallace, Michael J, Ahrar, Kamran, Hicks, Marshall E

“…Responses to liver-directed therapy with yttrium 90 microspheres (SIR-Spheres) and adjuvant intraarterial chemotherapy have occurred in patients with…”
Get more information

Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients Receiving Chemoradiation by Reyes-Gibby, Cielito C., DrPH, Chan, Wenyaw, PhD, Abbruzzese, James L., MD, Xiong, Henry Q., MD, Ho, Linus, MD, Evans, Douglas B., MD, Varadhachary, Gauri, MD, Bhat, Samrat, MBBS, Wolff, Robert A., MD, Crane, Christopher, MD

“…Abstract Pancreatic cancer is a lethal disease characterized by multiple disease-related symptoms. Chemoradiation therapy is a standard of treatment for…”
Get full text

Cytotoxic Chemotherapy for Pancreatic Cancer : Advances to Date and Future Directions by XIONG, Henry Q, CARR, Kelli, ABBRUZZESE, James L

“…Chemotherapy remains the mainstay of treatment for pancreatic cancer as most patients present with advanced disease, which precludes locoregional treatment…”
Get full text

NF‐κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells by Xiong, Henry Q., Abbruzzese, James L., Lin, Edward, Wang, Liwei, Zheng, Leizhen, Xie, Keping

“…The effect of blockade of NF‐κB activity on human pancreatic cancer angiogenesis was determined in an orthotopic xenograft model. Highly metastatic L3.3 human…”
Get full text

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines by Pino, Maria S, Shrader, Marissa, Baker, Cheryl H, Cognetti, Francesco, Xiong, Henry Q, Abbruzzese, James L, McConkey, David J

“…The epidermal growth factor receptor (EGFR) is considered an important therapeutic target in pancreatic cancer, but it is currently impossible to identify…”
Get full text